Refine
Has Fulltext
- yes (142) (remove)
Is part of the Bibliography
- yes (142)
Year of publication
Document Type
- Journal article (121)
- Preprint (9)
- Review (9)
- Conference Proceeding (1)
- Other (1)
- Working Paper (1)
Keywords
- metabolism (8)
- apoptosis (6)
- cosmology (6)
- crystallization (6)
- SARS-CoV-2 (5)
- cytokinins (5)
- qubit (5)
- COVID-19 (4)
- decoherence (4)
- evolution (4)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (138)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (7)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (6)
- Institut für Molekulare Infektionsbiologie (5)
- Center for Computational and Theoretical Biology (4)
- Institut für Experimentelle Biomedizin (4)
- Institut für Pharmakologie und Toxikologie (4)
- Institut für Virologie und Immunbiologie (4)
- Kinderklinik und Poliklinik (3)
- Institut für Humangenetik (2)
- Institut für Hygiene und Mikrobiologie (2)
- Institut für Informatik (2)
- Medizinische Klinik und Poliklinik I (2)
- Rudolf-Virchow-Zentrum (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Comprehensive Cancer Center Mainfranken (1)
- Fakultät für Mathematik und Informatik (1)
- Frauenklinik und Poliklinik (1)
- Institut für Mathematik (1)
- Institut für Organische Chemie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
- Julius-von-Sachs-Institut für Biowissenschaften (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
- Lehrstuhl für Biochemie (1)
- Lehrstuhl für Orthopädie (1)
- Pathologisches Institut (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 031A408B (1)
- CoG 721016–HERPES (1)
- ESF-ZDEX 4.0 (1)
Introduction
Pro-thrombotic events are one of the prevalent causes of intensive care unit (ICU) admissions among COVID-19 patients, although the signaling events in the stimulated platelets are still unclear.
Methods
We conducted a comparative analysis of platelet transcriptome data from healthy donors, ICU, and non-ICU COVID-19 patients to elucidate these mechanisms. To surpass previous analyses, we constructed models of involved networks and control cascades by integrating a global human signaling network with transcriptome data. We investigated the control of platelet hyperactivation and the specific proteins involved.
Results
Our study revealed that control of the platelet network in ICU patients is significantly higher than in non-ICU patients. Non-ICU patients require control over fewer proteins for managing platelet hyperactivity compared to ICU patients. Identification of indispensable proteins highlighted key subnetworks, that are targetable for system control in COVID-19-related platelet hyperactivity. We scrutinized FDA-approved drugs targeting indispensable proteins and identified fostamatinib as a potent candidate for preventing thrombosis in COVID-19 patients.
Discussion
Our findings shed light on how SARS-CoV-2 efficiently affects host platelets by targeting indispensable and critical proteins involved in the control of platelet activity. We evaluated several drugs for specific control of platelet hyperactivity in ICU patients suffering from platelet hyperactivation. The focus of our approach is repurposing existing drugs for optimal control over the signaling network responsible for platelet hyperactivity in COVID-19 patients. Our study offers specific pharmacological recommendations, with drug prioritization tailored to the distinct network states observed in each patient condition. Interactive networks and detailed results can be accessed at https://fostamatinib.bioinfo-wuerz.eu/.